[Lieyun Network (WeChat:ilieyun
) Beijing] Reported on July 9
Lieyun.com learned today that Juventas announced the completion of its A+ round financing, amounting to hundreds of millions of yuan. This round was led by CASI (Yingchuang Yuanda), with participation from Ruifu Medical Venture Capital Fund. Dalton Venture, the investor from the previous A round, also continued to participate in this financing.
Wang Guangming, Chairman of Juventas, stated that this round of financing will be primarily used to increase R&D investment, conduct clinical trials, and construct GMP-compliant manufacturing facilities.
In December 2018, Juventas announced the completion of its RMB 163 million Series A financing round, led by Danlu Capital, with participation from Dalton Venture and other institutions.
JuventasJuventas Biotechnology (Tianjin) Co., Ltd., founded in 2018, is a biopharmaceutical company focused on the research and development of innovative immune cell therapy drugs, dedicated to providing high-quality immune cell curative solutions for cancer patients worldwide.Juventas is committed to meeting clinical needs by building an innovative R&D pipeline. Leveraging its efficient R&D translation platform and adhering to stringent production and quality systems for cell therapy products, Juventas delivers safe, effective, and accessible immune cell therapy products to patients.
Currently, Juventas’ first immune cell therapy product, CNCT19, has had its Investigational New Drug (IND) application formally accepted by the National Medical Products Administration (NMPA). The company will continue to advance its subsequent pipeline products, providing effective therapeutic options for malignant hematologic tumors such as leukemia and lymphoma, as well as malignant solid tumors. Juventas currently operates a 1,300-square-meter R&D center in Beijing and a 1,400-square-meter GMP-compliant facility in Tianjin dedicated to the research, development, translation, and production of immune cell therapies. Additionally, a 7,000-square-meter GMP-compliant production base for immune cell drugs is under construction.